|
1
|
Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y,
Choi C, et al: The interactions between MicroRNA-200c and BRD7 in
endometrial carcinoma. Gynecol Oncol. 124:125–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bidus MA, Risinger JI, Chandramouli GV,
Dainty LA, Litzi TJ, Berchuck A, et al: Prediction of lymph node
metastasis in patients with endometrioid endometrial cancer using
expression microarray. Clin Cancer Res. 12:83–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Temkin SM and Fleming G: Current treatment
of metastatic endometrial cancer. Cancer Control. 16:38–45.
2009.PubMed/NCBI
|
|
4
|
Hill EK and Dizon DS: Medical therapy of
endometrial cancer: current status and promising novel treatments.
Drugs. 72:705–713. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park E, Gong EY, Romanelli MG and Lee K:
Suppression of estrogen receptor-alpha transactivation by thyroid
transcription factor-2 in breast cancer cells. Biochem Biophys Res
Commun. 421:532–537. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saini KS, Loi S, de Azambuja E,
Metzger-Filho O, Saini ML, Ignatiadis M, et al: Targeting the
PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast
cancer. Cancer Treat Rev. 39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bratton MR, Duong BN, Elliott S, Weldon
CB, Beckman BS, McLachlan JA and Burow ME: Regulation of
ERα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk:
Implications for breast cancer cell survival. Int J Oncol.
37:541–550. 2010.
|
|
8
|
Sun M, Paciga JE, Feldman RI, Yuan Z,
Coppola D, Lu YY, et al: Phosphatidylinositol-3-OH Kinase
(PI3K)/AKT2, activated in breast cancer, regulates and is induced
by estrogen receptor alpha (ERalpha) via interaction between
ERalpha and PI3K. Cancer Res. 61:5985–5991. 2001.PubMed/NCBI
|
|
9
|
Korkolopoulou P, Levidou G, Trigka EA,
Prekete N, Karlou M, Thymara I, et al: A comprehensive
immunohistochemical and molecular approach to the PI3K/AKT/mTOR
(phosphoinositide 3-kinase/v-akt murine thymoma viral
oncogene/mammalian target of rapamycin) pathway in bladder
urothelial carcinoma. BJU Int. 110:E1237–E1248. 2012. View Article : Google Scholar
|
|
10
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pal I and Mandal M: PI3K and Akt as
molecular targets for cancer therapy: current clinical outcomes.
Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: a play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vilar E, Perez-Garcia J and Tabernero J:
Pushing the envelope in the mTOR pathway: the second generation of
inhibitors. Mol Cancer Ther. 10:395–403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Creighton CJ, Fu X, Hennessy BT, Casa AJ,
Zhang Y, Gonzalez-Angulo AM, et al: Proteomic and transcriptomic
profiling reveals a link between the PI3K pathway and lower
estrogen-receptor (ER) levels and activity in ER plus breast
cancer. Breast Cancer Res. 12:R402010. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brody F, Hill S, Celenski S, Kar R, Kluk
B, Pinzone J and Fu S: Expression of ectonucleotide pyrophosphate
phosphodiesterase and peroxisome proliferator activated receptor
gamma in morbidly obese patients. Surg Endosc. 21:941–944. 2007.
View Article : Google Scholar
|
|
16
|
Loeffler J, Henke N, Hebart H, Schmidt D,
Hagmeyer L, Schumacher U and Einsele H: Quantification of fungal
DNA by using fluorescence resonance energy transfer and the Light
Cycler system. J Clin Microbiol. 38:586–590. 2000.PubMed/NCBI
|
|
17
|
Deregibus MC, Cantaluppi V, Doublier S,
Brizzi MF, Deambrosis I, Albini A and Camussi G: HIV-1-Tat protein
activates phosphatidylinositol 3-kinase/AKT-dependent survival
pathways in Kaposi’s sarcoma cells. J Biol Chem. 277:25195–25202.
2002.PubMed/NCBI
|
|
18
|
Lian Z, Niwa K, Onogi K, Mori H, Harrigan
RC and Tamaya T: Anti-tumor effects of herbal medicines on
endometrial carcinomas via estrogen receptor-α-related mechanism.
Oncol Rep. 15:1133–1136. 2006.PubMed/NCBI
|
|
19
|
Won YS, Lee SJ, Yeo SG and Park DC:
Effects of female sex hormones on clusterin expression and
paclitaxel resistance in endometrial cancer cell lines. Int J Med
Sci. 9:86–92. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pearce ST and Jordan VC: The biological
role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol
Hematol. 50:3–22. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cavazzoni A, Bonelli MA, Fumarola C, La
Monica S, Airoud K, Bertoni R, et al: Overcoming acquired
resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in
breast cancer cell clones. Cancer Lett. 323:77–87. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sabine VS, Sims AH, Macaskill EJ, Renshaw
L, Thomas JS, Dixon JM and Bartlett JM: Gene expression profiling
of response to mTOR inhibitor everolimus in pre-operatively treated
post-menopausal women with oestrogen receptor-positive breast
cancer. Breast Cancer Res Treat. 122:419–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito K, Utsunomiya H, Yaegashi N and Sasano
H: Biological roles of estrogen and progesterone in human
endometrial carcinoma - new developments in potential endocrine
therapy for endometrial cancer. Endocr J. 54:667–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Utsunomiya H, Suzuki T, Harada N, Ito K,
Matsuzaki S, Konno R, et al: Analysis of estrogen receptor alpha
and beta in endometrial carcinomas: correlation with ER beta and
clinicopathologic findings in 45 cases. Int J Gynecol Pathol.
19:335–341. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fatima I, Saxena R, Kharkwal G, Hussain
MK, Yadav N, Hajela K, et al: The anti-proliferative effect of
2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b) pyran is
potentiated via induction of estrogen receptor beta and p21 in
human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol.
138:123–131. 2013.
|
|
26
|
Lax SF: Molecular genetic pathways in
various types of endometrial carcinoma: from a phenotypical to a
molecular-based classification. Virchows Arch. 444:213–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matthews J and Gustafsson JA: Estrogen
signaling: a subtle balance between ER alpha and ER beta. Mol
Interv. 3:281–292. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Acconcia F and Kumar R: Signaling
regulation of genomic and nongenomic functions of estrogen
receptors. Cancer Lett. 238:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin CY, Ström A, Li Kong S, Kietz S,
Thomsen JS, Tee JB, et al: Inhibitory effects of estrogen receptor
beta on specific hormone-responsive gene expression and association
with disease outcome in primary breast cancer. Breast Cancer Res.
9:R252007. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castoria G, Migliaccio A, Bilancio A, Di
Domenico M, de Falco A, Lombardi M, et al: PI3-kinase in concert
with Src promotes the S-phase entry of oestradiol-stimulated MCF-7
cells. EMBO J. 20:6050–6059. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Acconcia F, Totta P, Ogawa S, Cardillo I,
Inoue S, Leone S, et al: Survival versus apoptotic 17
beta-estradiol effect: role of ER alpha and ER beta activated
non-genomic signaling. J Cell Physiol. 203:193–201. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Paruthiyil S, Parmar H, Kerekatte V, Cunha
GR, Firestone GL and Leitman DC: Estrogen receptor beta inhibits
human breast cancer cell proliferation and tumor formation by
causing a G(2) cell cycle arrest. Cancer Res. 64:423–428. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma L, Liu Y, Geng C, Qi X and Jiang J:
Estrogen receptor β inhibits estradiol-induced proliferation and
migration of MCF-7 cells through regulation of mitofusin 2. Int J
Oncol. 42:1993–2000. 2013.
|
